Effects of liraglutide 3.0 mg on weight and risk factors in hispanic versus non-hipanic populations: Subgroup analysis from scale randomized trials

Endocrine Practice

Volumn 22, Issue 11, 2016, Pages 1277-1287

  O'Neil, Patrick M ^a   Garvey, W Timothy ^b   Gonzalez Campoy, J Michael ^c   Mora, Pablo ^d   Ortiz, Rafael Violante ^e   Guerrero, German ^f   Claudius, Birgitte ^g   Pi Sunyer, Xavier ^h  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Minnesota Center for Obesity Metabolism and Endocrinology   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^f NOVO NORDISK INC   (United States)

^g NOVO NORDISK A S   (Denmark)

^h Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIRAGLUTIDE; PLACEBO; TRIACYLGLYCEROL; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; FEMALE; GASTROINTESTINAL DISEASE; HISPANIC; HUMAN; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; POST HOC ANALYSIS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK FACTOR; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ETHNOLOGY; OUTCOME ASSESSMENT; OVERWEIGHT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT (HEALTH CARE); OVERWEIGHT; RISK FACTORS; WEIGHT LOSS;

EID: 85021856177     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP151181.OR     Document Type: Article

References (33)

1. Lopez-Rangel E. Latino culture. In: Fisher NL, ed. Cultural and Ethnic Diversity: A Guide for Genetics Professionals. Baltimore, MD: Johns Hopkins University Press; 1996: 19-35.
2. Lindberg NM, Stevens VJ, Halperin RO. Weight-loss interventions for Hispanic populations: The role of culture. J Obes. 2013;2013:542736
3. Karter AJ, Ferrari A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2012;287:2519-2527.
4. McWilliams JM, Meara E, Zaslavsky AM, Ayanian JZ. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: US trends from 1999 to 2006 and effects of Medicare coverage. Ann Intern Med. 2009;150:505-515.
5. Zhang Q, Wang Y, Huang ES. Changes in racial/ethnic disparities in the prevalence of type 2 diabetes by obesity level among US adults. Ethnic Health. 2009;14:439-457.
6. U.S. Census Bureau. Changing Nation: Percent Hispanic of the U.S. Population: 1980-2050. 2013 population estimates.
7. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806-814.
8. Lindberg NM, Stevens VJ. Review: weight-loss interventions with Hispanic populations. Ethn Dis. 2007;17:397-402.
9. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study. Obesity (Silver Spring). 2014;22:5-13.
10. Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: A combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med. 2014;126:7-18.
11. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22.
12. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes randomized clinical trial. JAMA. 2015;314:687-699.
13. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after lowcalorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes. 2013;37:1443-1451.
14. Blackman A, Foster G, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (London) 2016;40:1310-1319.
15. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-3045.
16. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice, 2003.
17. FAO/WHO/UNU. Human energy requirements. Report of a joint FAO/WHO/UNU expert consultation. FAO: food and nutrition technical report series 1. Rome: FAO/WHO/ UNU, 2004
18. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606-1616.
19. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the oncedaily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843-854.
20. Lean ME, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond). 2014;38:689-697.
21. Poston WS, Reeves RS, Haddock CK, et al. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. Int J Obes. 2003;27:1486-1493.
22. Khorgami Z, Arheart KL, Zhang C, Messiah SE, de la Cruz-Muñoz N. Effect of ethnicity on weight loss after bariatric surgery. Obes Surg. 2015;25:769-776.
23. Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: Analysis of effectivenes and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012;124:21-32.
24. Peterson GE, Pollom RD. Liraglutide in clinical practice: dosing, safety and efficacy. Int J Clin Pract Suppl. 2010;167:35-43.
25. Fraga L, Garcia JA. The evolving Latino community and pan-ethnicity: Explorations into the confluence of interactions, networks and identity. In: Latino Lives in America: Making it Home. Philadelphia, PA: Temple University Press; 2010: 145-176.
26. Calderón J. "Hispanic" and "Latino": The viability of categories for panethnic unity. Lat Am Perspect. 1992; 19:37-44.
27. Gadde KM, Allison DB, Ryan DH, et al. Effects of lowdose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352.
28. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245-256.
29. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev. 2009;10:333-341.
30. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
31. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8:270-278.
32. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year followup study. Lancet Diabetes Endocrinol. 2014;2:474-480.
33. Jensen MD, Ryan DH, Donato KA, et al. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society Published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from The Obesity Expert Panel, 2013. Obesity (Silver Spring). 2014;22 Suppl 2:S5-S39.